AACR Annual Meeting 2018

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 43.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accrediation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Wednesday, May 30. (Link to survey will be posted below prior to the conference.) Certificates will only be issued to those who complete the survey, which will be available on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.


Statement of Educational Need, Target Audience, and Learning Objectives
The fight against cancer is rapidly progressing, with the accelerating pace of discoveries in the basic, translational and clinical sciences. This is due in large part to the advent of new technologies, such as advanced live imaging techniques and liquid biopsies, and our increased understanding of the importance of the contribution of the immune system to cancer and development of new immunotherapies. However, understanding and combating the processes of cancer initiation, progression, and response to treatment require a multidisciplinary approach. This meeting will bring together cancer biologists and clinical oncologists with engineers and physical scientists to develop quantitative approaches and ask new questions to develop better strategies for curing cancer. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists will increase the contributions of laboratory research to drug development as well as patient care; transform the design and conduct of clinical research protocols; and create a forum for the rapid translation of laboratory research findings from "bench-to-bedside" for the benefit of improving patient outcomes. This meeting also acts as a forum for the exchange of information between scientists and clinicians about the epidemiological implications of cancer incidence, in the effort to eliminate cancer health disparities.

Despite the tremendous progress in the field, cancer continues to be an enormous public health challenge worldwide, accounting for one in every four deaths that occur around the world. In the United States (U.S.) alone, it is predicted that 600,920 people will die from some form of cancer in 2017, making it the second most common cause of death after heart disease.  One of the challenges we face is that cancer is comprised of more than 200 different diseases.  For many of the most commonly diagnosed cancers in the U.S.—including lung, prostate, ovarian, and cervical cancer—incidence has been declining for more than a decade.  However, incidence of other forms of cancer—including endometrial, liver, thyroid, and childhood cancer and leukemia—have been on the rise. Overall five-year relative survival rates for U.S. patients vary widely depending on the form of cancer and the stage at which it is diagnosed. Incidence, diagnosis, access to treatment, and survival rates are also impacted by the cancer health disparities that exist in certain segments of the U.S. population, with older and underprivileged populations often witnessing higher incidences of cancer and mortality.

This conference will bring together over 21,000 investigators from the basic, translational, and clinical disciplines and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations.  In order to provide the most advanced technologies and treatments, it is critical to bridge the gap between physicians who are answering fundamental questions about cancer biology and clinicians who are applying the latest diagnostic and treatment advances to patient care. As the incidence of cancer continues to increase, the fields of cancer prevention and early interception offer unprecedented opportunities to decrease the worldwide burden of cancer.

 After participating in this CME activity, physicians should be able to:

  1. Assess the technological advances and tools, such as liquid biopsies, being used to accelerate progress in cancer research and improve early detection and early interception, with the ultimate goal of extending patients' lives and improving their quality of life.
  2. Articulate how advances in precision cancer medicine are leading to improved patient outcomes.
  3. Incorporate the latest research findings regarding therapies and treatment options, including immunotherapy, in a variety of cancer types to improve patient outcomes.
  4. Formulate new strategies integrating multidisciplinary scientific and clinical research efforts towards the prevention and early detection of cancer.
  5. Identify factors which impact the diagnosis, treatment, and prevention of various forms of cancers in patients from different populations.
  6. Develop collaborations amongst physicians, researchers, and clinician-scientists to advance the cause of treating and preventing cancer.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the meeting app, online planner, or conference website and is available for download.

Acknowledgment of Financial or Other Support
This activity is supported by grants and will be disclosed at the activity. 

Questions about CME?
Please contact the Office of CME at (215) 440-9300 or